CERo Therapeutics Holdings (CERo Therapeutics Holdings) EV-to-EBIT : (As of May. 13, 2024)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CERo Therapeutics Holdings's Enterprise Value is $14.99 Mil. CERo Therapeutics Holdings does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2022. Therefore, GuruFocus does not calculate CERo Therapeutics Holdings's EV-to-EBIT at this moment.

The historical rank and industry rank for CERo Therapeutics Holdings's EV-to-EBIT or its related term are showing as below:

CERO' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.79 Med: 0 Max: 0
Current: -1.25

CERO's EV-to-EBIT is ranked worse than
100% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs CERO: -1.25

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. CERo Therapeutics Holdings's Enterprise Value for the quarter that ended in Dec. 2022 was $0.00 Mil. CERo Therapeutics Holdings does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2022. Therefore, GuruFocus does not calculate CERo Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % at this moment.

CERo Therapeutics Holdings EV-to-EBIT Historical Data

The historical data trend for CERo Therapeutics Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings EV-to-EBIT Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

EV-to-EBIT

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
EV-to-EBIT	-	-

Competitive Comparison of CERo Therapeutics Holdings's EV-to-EBIT

For the Biotechnology subindustry, CERo Therapeutics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's EV-to-EBIT falls into.

CERo Therapeutics Holdings EV-to-EBIT Calculation

CERo Therapeutics Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	14.990	/
	=

CERo Therapeutics Holdings (NAS:CERO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

CERo Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2022 )	=	EBIT	/	Enterprise Value (Q: Dec. 2022 )
	=		/	0
	=	%

CERo Therapeutics Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024